MARKET

LABT

LABT

Lakewood-Amedex
NASDAQ
0.5775
-0.0059
-1.01%
Pre Market: 0.5200 -0.0575 -9.96% 08:48 10/21 EDT
OPEN
0.5841
PREV CLOSE
0.5834
HIGH
0.6204
LOW
0.5700
VOLUME
122.28K
TURNOVER
--
52 WEEK HIGH
98.20
52 WEEK LOW
0.5600
MARKET CAP
1.37M
P/E (TTM)
-0.1987
1D
5D
1M
3M
1Y
5Y
1D
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Benzinga · 5h ago
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
PR Newswire · 5h ago
Weekly Report: what happened at LABT last week (1012-1016)?
Weekly Report · 2d ago
Weekly Report: what happened at LABT last week (1005-1009)?
Weekly Report · 10/12 10:38
Lakewood-Amedex announces preclinical data from Bisphosphocin studies
TipRanks · 10/07 12:10
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/07 12:05
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
PR Newswire · 10/07 12:02
Weekly Report: what happened at LABT last week (0928-1002)?
Weekly Report · 10/05 10:37
More
About LABT
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.

Webull offers Lakewood-amedex Biotherapeutics Inc stock information, including NASDAQ: LABT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LABT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LABT stock methods without spending real money on the virtual paper trading platform.